• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Mycetoma is added to WHO List of ‘Neglected Tropical Diseases’

Move helps bring the disease to the attention of governments and funders

Geneva, Switzerland — 28 May 2016

By adding the devastating infection mycetoma to WHO’s official list of ‘neglected tropical diseases,’ WHO Member States took an important step in boosting national and global responses to this woefully neglected disease and addressing the suffering of patients.

“Including mycetoma on the WHO List gives the disease the political prominence it so desperately needed. Funding bodies can now consider taking up the disease. It will also allow global programmes to be set up, which would better define the epidemiology, the risk factors, as well as treatment strategies, and early identification of cases,” said Dr Nathalie Strub Wourgaft, DNDi Medical Director.

Mycetoma is a devastating, slow-growing bacterial or fungal infection, which develops into a chronic infection of the skin tissues and, if left untreated, eventually results in amputation. Children and young adults are particularly at risk. With existing anti-fungals and surgery, only 35% of people living with the fungal form of the disease, known as eumycetoma, are cured. Infection can come from the soil or animal dung, and it is thought that it enters the body after the skin has been pricked, for example by a thorn.

“Mycetoma patients are among the most neglected of the neglected. They are poor, stigmatized, and often live in remote and rural areas. Today’s decision is a recognition of their plight. We have been struggling for international recognition of mycetoma because we cannot fight this alone. The only way we can truly help these people is by bringing in resources from the global health community,” said Dr Ahmed Fahal, Professor of Surgery at the University of Khartoum and Director of the Mycetoma Research Centre (MRC).

Eumycetoma patients have received little attention and virtually no research and development has addressed their needs to date.

“There is a desperate need for safe, effective, and affordable treatments; rapid and accurate diagnostics; and a good deal more epidemiological data needs to be collected in the entire ‘Mycetoma Belt,’ in countries like Brazil, Chad, Ethiopia, India, Mexico, Senegal, Somalia, Sudan, and Yemen,” said Dr Nathalie Strub Wourgaft.

Together with Japanese pharmaceutical company Eisai Co., Ltd, and the MRC, DNDi will soon be launching a clinical trial for fosravuconazole, a potential new treatment of eumycetoma.

DNDi and the MRC acknowledge the work of many in achieving this greater political recognition for mycetoma.

“On behalf of my dedicated staff at the MRC and the thousands of patients that have entered our doors, I would like to thank all of the advocates that have joined us in achieving this victory. This is a truly an example of global solidarity, where people from around the globe joined forces – putting aside politics, religion, and region – to help neglected patients from Sudan and other afflicted countries. We have seen the birth of the ‘Mycetoma Movement.’ Now is the time to get to work,” said Dr Ahmed Fahal.

To learn how a simple thorn prick can lead to this debilitating and fatal infection, please visit the DNDi microsite that describes the disease, the lives of people affected, and the work and staff of the MRC.

Media Contacts

DNDi North America
Ilan Moss
imoss@dndi.org
Tel.: +1 646 266 5216

DNDi Japan
Mari Matsumoto
mmatsumoto@dndi.org
+81 90 8107 9778

Additional Resources

  • Read the visual story on mycetoma 
Policy advocacy Mycetoma

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License